Most cytotoxic vials are bought against a fixed course. Four cycles, six cycles, a number the oncologist writes down at the start. Pemetrexed 500 mg inj is the exception in a lung oncology range, because in the maintenance setting, the labeling does not name an endpoint at all. Dosing continues on day 1 of each 21-day cycle until the disease progresses or the patient cannot tolerate it. One patient entering maintenance is therefore an open order, and the only two things that close it are written into the label.

Pemetrexed Injection IP 500mg Uses

The approved Pemetrexed Injection IP 500mg uses sit in two diseases and, within lung cancer, in one histology. In nonsquamous non small cell lung cancer the drug is used with cisplatin as initial treatment, as single agent maintenance after four cycles of platinum based chemotherapy without progression, and as a single agent after prior chemotherapy. In malignant pleural mesothelioma it is given with cisplatin where the disease is unresectable or curative surgery is not an option.

Squamous cell and non-small cell lung cancer is excluded. The labeling states it directly, and because the maintenance setting is where most of the 500 mg volume goes, a tender built on the phrase lung cancer alone will be wrong about which patients the product can serve.

Pemetrexed 500 mg Inj Side Effects

Myelosuppression sets the rhythm of treatment. Blood counts are checked before every cycle, and the dose does not go ahead unless neutrophils reach 1,500 per cubic mm and platelets 100,000. The pemetrexed 500 mg inj side effects that trigger a dose reduction are listed in the ladder above, and they are the ones that matter commercially as well as clinically, because each one permanently lowers what that patient will consume.

Beyond the counts, mucositis is singled out for a steeper cut than most toxicities, at 50 percent of the previous dose rather than 75. Fatigue, nausea and rash are common. Rash is the reason dexamethasone 4 mg twice daily is given the day before, the day of and the day after each infusion, as prophylaxis that has to be dispensed in advance rather than reached for when a rash appears.

Three findings end treatment outright rather than reducing it: grade 3 or 4 neurologic toxicity, severe skin toxicity, and interstitial pneumonitis. Renal toxicity pauses rather than ends it, with treatment withheld until creatinine clearance returns to 45 mL per minute or above.

One Vial Per Cycle, Until the Disease Says Stop

The maintenance indication covers locally advanced or metastatic nonsquamous non-small cell lung cancer that has not progressed after four cycles of platinum-based first-line chemotherapy. From that point, the patient receives 500 mg per square meter on day 1 of every 21-day cycle, as a single agent, for as long as it keeps working.

Run the arithmetic, and the supply picture changes shape. A 21-day cycle gives about seventeen cycles in a calendar year. Every adult dose at 500 mg per square meter draws at least one 500 mg vial, because a patient of one square meter already needs the full vial, and almost every adult is larger. So a single maintenance patient consumes something close to seventeen of these vials a year, every year, until progression. This is arithmetic from the cycle length rather than a sales forecast, and real centers see patients stop for reasons the label cannot predict.

That open-ended profile is unusual among cytotoxics, and it changes how a distributor should treat the line. A platinum agent, such as carboplatin 450 mg, is drawn down over a defined induction course and then stops. A second-line agent, such as docetaxel 120 mg injection, is used when a patient progresses. The 500 mg pemetrexed vial sits in neither pattern, and ordering it on the same assumptions as the rest of the oncology shelf is how centers run short mid-course.

The Dose Ladder Only Goes Down

Two things end or shrink that open order, and the second is what buyers miss. Progression is obvious. The other is the dose modification schedule, which has a feature worth looking at directly: it contains no route back up.

A patient who drops to 75 percent stays there. The labeling gives no criterion for returning to the full dose once the reduction has been made, and after two reductions a further grade 3 or 4 event means stopping altogether. Add the gate before each cycle, which requires a neutrophil count of at least 1,500 per cubic mm and platelets of at least 100,000, and the pattern is clear. Consumption per patient declines over the course and never recovers.

For a 1.7 square meter patient, a reduction to 75 percent takes the dose from about 850 mg to roughly 640 mg. The 500 mg vial is still needed. What changes is everything drawn around it, which is why reductions show up in a usage report as a drop in small vial movement while the 500 mg count holds steady.

Powder or Ready to Dilute: Say Which Before You Quote

Pemetrexed at 500 mg now exists in two forms, and recent approvals have moved toward the second. The newer United States labeling covers a ready-to-dilute solution supplied at 25 mg per mL, which puts 500 mg in a 20 mL vial. Indian products carrying the IP designation are commonly supplied as lyophilized powder for reconstitution. Both end up diluted in 0.9 percent sodium chloride to 100 mL for a 10-minute infusion.

What differs is the work and the risk around that step:

• The powder needs reconstitution in a cytotoxic cabinet before dilution, which is one more manipulation of a hazardous drug.
• The solution removes reconstitution and arrives at a fixed concentration, which reduces preparation error.
• Diluted solution that is not used at once is refrigerated at 2 to 8°C and discarded after 24 hours, whichever form it started in.
• Calcium-containing diluents are not used with either, so Lactated Ringer solution is out.

Pemetrexed 500 mg Price in India

At the time of writing, a 500 mg vial from an Indian brand was listed on a national pharmacy site at about 2,289 rupees against a maximum retail price of 2,544 rupees, and showed as sold out, as did the originator brand alongside it. Those are retail figures rather than trade rates, and they move.

Set them next to the smaller vial, and something useful appears. The same site listed the 100 mg at about 797 rupees. A 1.7 square meter patient needing roughly 850 mg buys one 500 mg vial and four 100 mg vials, which comes to about 5,477 rupees at those retail figures. The small vials account for close to 58 percent of that bill while supplying about 44 percent of the milligrams. Dose banding, where a center standardizes doses to reduce vial waste, is worth more on this molecule than the headline pemetrexed 500 mg price in India suggests.

On the supply side, cytotoxic handling dominates the cost base: containment, dedicated or campaigned areas, operator protection, and lyophilization, where the powder form is made. Quantity and destination market do the rest. Rates are quoted per order for trade buyers and PCD pharma partners alike.

Pemetrexed 500 mg Inj Manufacturer in India

Torso Healthcare is a WHO GMP-certified injectable manufacturer based in Baddi, Himachal Pradesh, supplying hospitals, distributors, and franchise partners across India and export markets from a sterile injectable facility that also serves the wider critical care injectable range. A buyer assessing a pemetrexed 500 mg inj manufacturer in India is usually weighing whether cytotoxics run in a dedicated area, which presentation is produced, and whether both strengths come from the same supplier, since a maintenance patient needs continuity of supply over months rather than weeks.

Dossier support and batch documentation are shared on request under standard contract supply terms.

Hospitals, distributors and franchise partners sourcing pemetrexed 500 mg inj in bulk, or supplying a lung oncology program that runs maintenance patients month after month, can send your order details with the presentation, strengths and destination market, and Torso Healthcare will reply with current rates and lead times.

Maintenance dosing, dose modification rules, presentations, preparation, storage, and safety data on this page follow the 2022 FDA prescribing information and the earlier pemetrexed labeling.

Frequently Asked Questions

How long does a maintenance patient stay on treatment?

The labeling sets no fixed duration. Dosing continues every 21 days until the disease progresses or toxicity makes it untenable. That is why a maintenance patient behaves like a standing order rather than a fixed course, and why forecasting from induction numbers alone understates the 500 mg line.

Can a reduced dose be put back up later?

The labeling provides no route back to the full dose after a reduction. Reductions are to 75 or 50 percent of the previous dose, depending on the event, and a recurrence after two reductions means stopping permanently. Neurologic toxicity at grade 3 or 4 ends treatment immediately.

Is an oral vitamin B12 tablet acceptable instead of the injection?

No. The labeling calls for 1 mg of vitamin B12 by intramuscular injection one week before the first dose and every three cycles after it, and states that oral B12 is not an acceptable substitute. A center starting a patient needs the injection in hand, which is why buyers often take methylcobalamin 2500 mcg in the same consignment, with the prescriber choosing form and strength.

Does the 500 mg replace the 100 mg vial in an order?

No, the two work together. The 500 mg carries the bulk of each dose, and the smaller vial makes up the remainder, so both move on the same prescription. The 100 mg vial strength covers that side of the arithmetic in detail.

What must a quote specify to be comparable?

The presentation, because pemetrexed at this strength exists as a lyophilized powder and as a ready-to-dilute solution, and the two carry different storage and preparation requirements. Quantity, pack configuration, and destination market complete the picture. Two quotes that name only the strength are not comparable.

Disclaimer: This page is intended for pharmaceutical businesses, trade buyers, and healthcare professionals as product reference information only. It is not an advertisement to the public, not medical advice, and not a recommendation for treatment. Pemetrexed is a prescription cytotoxic medicine and must be prescribed and administered only under qualified medical supervision.